Dyax Corp. to Participate in the 25th Annual ROTH Conference

Before you go, we thought you'd like these...
Before you go close icon

Dyax Corp. to Participate in the 25thAnnual ROTH Conference

BURLINGTON, Mass.--(BUSINESS WIRE)-- Dyax Corp. (NAS: DYAX) announced today that the Company will participate in the 25th Annual ROTH Conference, being held March 17-20, 2013, at the Ritz-Carlton Laguna Niguel in Dana Point, CA. Gustav Christensen, President and Chief Executive Officer of Dyax, will present on Tuesday, March 19 at 5:30 PM (PT). Mr. Christensen will provide a corporate update regarding the Company's key value drivers - KALBITOR® (ecallantide) and the angioedema portfolio, as well as the Licensing and Funded Research Program (LFRP).

This presentation will be webcast live and may be accessed by visiting the Investor Relations section of the company website at www.dyax.com. The webcast will also be available on the Dyax website for a limited period of time following the conferences.


About Dyax

Dyax is a fully integrated biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs. The Company's key value drivers are the KALBITOR® (ecallantide) business and the angioedema portfolio, as well as the Licensing and Funded Research Program (LFRP).

Dyax developed KALBITOR on its own and, since February 2010, the Company has been selling it in the United States for the treatment of acute attacks of hereditary angioedema (HAE) in patients 16 years of age and older. Outside the United States, the Company has established partnerships to obtain regulatory approval for and commercialization of KALBITOR in certain markets and is evaluating opportunities in others.

The Company is currently developing products to expand its angioedema portfolio, including a suite of diagnostic assays to identify plasma kallikrein mediated (PKM) angioedema and a therapeutic candidate, DX-2930, for the prophylactic treatment of HAE.

KALBITOR and DX-2930 were identified using Dyax's patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly through the LFRP. This program has provided the Company a portfolio of product candidates being developed by its licensees, which currently includes 13 royalty and/or milestone bearing product candidates in various stages of clinical development, including three in Phase 3 trials.

Dyax is headquartered in Burlington, Massachusetts. For additional information about Dyax, please visit www.dyax.com.



Dyax Corp.
Jennifer Robinson, 617-250-5741
Associate Director, Investor Relations and
Corporate Communications
jrobinson@dyax.com

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:

The article Dyax Corp. to Participate in the 25th Annual ROTH Conference originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners